Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–574 of 574 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Tumor and Hematologic Malignancies Clear all
Recruiting No phase listed Observational

Umbilical Cord Blood Transplantation From Unrelated Donors

NCT03016806
View directory record Official record
Conditions
Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Interventions
Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
Radiation · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Months to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 2 Interventional

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

NCT00002504
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, recombinant interferon alfa
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
5
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

NCT05599932
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Siremadlin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 30, 2026, 1:31 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT06823167
View directory record Official record
Conditions
Solid Malignancies, Hematologic Malignancies
Interventions
IM-1021
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00352443
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
everolimus, lapatinib ditosylate
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 30, 2026, 1:31 PM EDT
Terminated Not applicable Interventional Results available

eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors

NCT04081298
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Health Education, Physical Activity, Health Promotion and Education: Text Messages, Health Promotion and Education: Web Site, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 30, 2026, 1:31 PM EDT
Recruiting Not applicable Interventional

Implementation of an Oral Chemotherapy Adherence Intervention

NCT06989489
View directory record Official record
Conditions
Solid Tumor, Hematologic Malignancy
Interventions
Multilevel Adherence Intervention
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

NCT02211755
View directory record Official record
Conditions
Neoplasms, Myelodysplastic Syndromes, Lymphomas
Interventions
Bortezomib plus Clofarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 1:31 PM EDT
Recruiting Phase 1 Interventional

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT05768932
View directory record Official record
Conditions
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
Interventions
BAL0891, Tislelizumab, Paclitaxel
Drug · Combination Product
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 30, 2026, 1:31 PM EDT
Completed No phase listed Observational

Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients

NCT02464098
View directory record Official record
Conditions
Diarrhea
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00002625
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Lymphoma
Interventions
topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 30, 2026, 1:31 PM EDT
Terminated No phase listed Observational

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

NCT02840110
View directory record Official record
Conditions
B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product
Other
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 30, 2026, 1:31 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work

NCT05038384
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

NCT00652626
View directory record Official record
Conditions
MDS, AML, Solid Tumors, Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions
azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Berkeley, California • Hialeah, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment

NCT04788758
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Educational Intervention, Screening Questionnaire Administration, Referral, Questionnaire Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 30, 2026, 1:31 PM EDT
Terminated Phase 1 Interventional

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

NCT06188208
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced Hematologic Tumors
Interventions
VVD-130850, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 4 Interventional

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

NCT04745910
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome
Interventions
Pegloticase, Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 1 Interventional

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

NCT01039155
View directory record Official record
Conditions
Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Not applicable Interventional Results available

Shared Healthcare Actions and Reflections Electronic Systems in Survivorship

NCT04337203
View directory record Official record
Conditions
Cancer, Survivorship, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
SHARE-S Implementation Program
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

NCT01912222
View directory record Official record
Conditions
Advanced Solid Tumors, Hematologic Malignancies
Interventions
IXAZOMIB
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Fairway, Kansas • Cleveland, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 30, 2026, 1:31 PM EDT
Completed Phase 2 Interventional Results available

Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

NCT00578942
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
Interventions
Campath Purged Non-myeloablative ASCT
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
17 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 30, 2026, 1:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

NCT04730349
View directory record Official record
Conditions
Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions
Nivolumab, NKTR-214
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 30, 2026, 1:31 PM EDT